The 4th International Symposium on APS Type 1 (VIRTUAL EVENT)
The 4th International Symposium on APS Type 1
September 18, 2021 @12-4pm EDT
VIRTUAL EVENT >> LINK TO FOLLOW*
Each presentation will be 30 mins, followed by 15 mins Q&A
12:00-12:05 Introductions (Prof. Jennifer Orange, The APS Type 1 Foundation & Dr. Irene Lara-Corrales, SickKids)
12:05-12:50 Paul Bastard (Necker Hospital and Rockefeller University), Autoantibodies against type I IFNs in patients with APS-1
12:50-1:35 Dr. Mihalis Lionakis (NIH), Clinical management of COVID-19 and vaccination responses to SARS-CoV-2 in APS-1/APECED patients
1:35-1:45 Health Break
1:45-2:30 Sara Vazquez (UCSF), Discovery of novel, clinically correlated autoantibodies in APS-1 by high-throughput PhIP-Seq
2:30-3:30 Dr. Maureen Su (UCLA), AIRE & Cancer
3:30-3:55 Breakout Rooms
BoG1: Newly diagnosed patients of APS Type 1
BoG2: Managing Calcium and Adrenal Insufficiency (Dr. Cheri Deal - Université de Montréal and CHU Ste-Justine)
BoG3: Clinicians/Scientists Meet and Greet
BoG4: Children/ Youth Meet and Greet
3:55-4:00 Closing and Thank Yous
* Tickets are available for free through Eventbrite but pre-registration is required. You will receive a zoom webinar link in mid-September upon successful registration. Please note that ticket registration will close on Sept 17th at 12PM EDT and each attendee must register separately in advance using their own email address.
Bios of speakers
Paul Bastard is an MD-PhD student in pediatrics and immunology, focusing on the genetic and immunological predisposition to severe viral diseases. Paul works at the Necker Hospital in Paris and the laboratory of Human genetics of infectious diseases, headed by Jean-Laurent Casanova.
Dr. Irene Lara-Corrales is an Associate Professor of Paediatrics at the University of Toronto and a Staff Physician in Paediatric Dermatology at The Hospital for Sick Children (SickKids) in Toronto, Canada. She completed her medical training and paediatric residency at the University of Costa Rica, in San Jose, Costa Rica and her paediatric dermatology training at SickKids. She obtained a master of science degree from the University of Toronto. She is involved in numerous clinical and research endeavours, as well as in teaching commitments. He co-directs the Genodermatoses, Epidermolysis Bullosa, Vascular Tumors and Café-au-Lait Screening clinics at SickKids. She is also the co-chair of the hospital’s Wound Care Committee. Her research interests include genodermatoses, inflammatory diseases, vascular anomalies and dermatologic problems in hematology/oncology patients.
Dr. Michail S. Lionakis M.D., Sc.D., Chief, Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, obtained his MD and ScD from the University of Crete, Greece. He did clinical and research training at MD Anderson Cancer Center, Baylor College of Medicine, and NIH. His IRB-approved APS Type-1/APECED clinical research protocol aims to understand the mechanisms of autoimmunity and fungal susceptibility and improve diagnostic and therapeutic strategies for patients.
Dr. Maureen A. Su, Professor of Microbiology/Immunology and Medical Genetics and Pediatric Endocrinology at UCLA, received her bachelor’s, master’s and medical degrees from Harvard. She completed her pediatrics residency and fellowship in endocrinology at UCSF. Dr. Su seeks to understand what causes autoimmune diseases in order to develop therapeutics to prevent and treat the underlying immune condition. Her work focuses on APS Type 1, GBS/CIDP, and T1D.
Sara Vazquez is an MD/PhD student in the labs of Mark Anderson and Joe Derisi at UCSF. She has worked to improve PhIP-seq protocols to enable scalable autoantibody discovery in a wide variety of disease contexts, including APS1, sporadic autoimmune diabetes, and COVID-related autoimmunity. Prior to medical school, Sara worked in Tom Serwold’s lab at the Joslin Diabetes Center optimizing hematopoietic stem cell isolation in autoimmune-prone mouse strains. She received her undergraduate degree in Stem Cell and Developmental Biology at Harvard College. Her long-term goal is to combine molecular autoantigen discovery with therapeutic approaches for re-establishing immune tolerance in autoimmunity.
The APS Type 1 Foundation gratefully acknowledges support from SickKids Hospital & Julia's Fund at the SickKids Foundation.
To learn more, please check out: https://apstype1.org/